Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07352293 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Value of Methotrexate in NCES for Stable Vitiligo

StatusCompleted
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 6 more changesShow less
    • Enrollment target: estimated 20 to confirmed 21
    • Primary completion date changed from estimate of Sep 2026 to Sep 10, 2026
    • Study completion date changed from estimate of Sep 2026 to Sep 21, 2026
    • Eligibility criteria expanded, about 11 words
    • Study description expanded, about 15 words
    • Publications: details revised at 11 of 11 entries
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised
    v4
  3. Start date changed from estimate of Jan 2026 to Mar 3, 2026v3
  4. Phase: Phase 3 to Phase 4v2 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Primary endpoints: 1 to 2
    • Study description shortened, about 44 words
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cairo University
1,562 trials monitored
See 18 trials at risk
The goal of this clinical trial is to learn if adding a six months course of Methotrexate would improve the results of non cultured epidermal suspension (NCES) in adult patients with acral and resistant vitiligo lesions over the elbows and knees. researchers will compare results of NCES in two groups one group will receive Methotrexate for 3 months prior to the procedure and 3 months after the procedure, while the other group will not receive the drug. Patients will receive PUVA hand \& feet 3 times/week for 3 months after NCES during this period they will be followed up monthly to evaluate repigmentation.
Trial Details
NCT Number NCT07352293
Lead Sponsor Cairo University
Conditions
(from sponsor)		 Vitiligo
Related terms Vitiligo
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov